{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T03:54:30Z","timestamp":1793850870627,"version":"4.6.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T00:00:00Z","timestamp":1597708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T00:00:00Z","timestamp":1597708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG066429"],"award-info":[{"award-number":["R01AG066429"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["RF1AG054199"],"award-info":[{"award-number":["RF1AG054199"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG054672"],"award-info":[{"award-number":["R01AG054672"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R56AG057469"],"award-info":[{"award-number":["R56AG057469"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P30AG0138423"],"award-info":[{"award-number":["P30AG0138423"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P30AG0138423"],"award-info":[{"award-number":["P30AG0138423"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R21NS104609"],"award-info":[{"award-number":["R21NS104609"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007625","name":"Cure Alzheimer's Fund","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100007625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006312","name":"BrightFocus Foundation","doi-asserted-by":"publisher","award":["A2016551S"],"award-info":[{"award-number":["A2016551S"]}],"id":[{"id":"10.13039\/100006312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012513","name":"Coins for Alzheimer's Research Trust","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100012513","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008539","name":"CurePSP","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100008539","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neuronal accumulation of misfolded microtubule-associated protein tau is a hallmark of neuropathology in Alzheimer\u2019s disease, frontotemporal dementia, and other tauopathies, and has been a therapeutic target. Microglia can spread tau pathology by secreting tau-containing exosomes, although the specific molecular target is yet to be identified for the therapeutic intervention. P2X purinoceptor 7 (P2RX7) is an ATP-gated cation channel, enriched in microglia and triggers exosome secretion. The purpose of the study is to examine the therapeutic effect of an orally applicable, CNS-penetrant P2RX7 specific inhibitor on the early disease stage of a tauopathy mouse model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Three-months-old P301S tau mice were treated with P2RX7-specific inhibitor GSK1482160 or vehicle for 30\u2009days, followed by behavioral, biochemical and immunohistochemical assessment. GSK1482160 was also tested for exosome secretion from primary cultured murine astrocytes, neurons and microglia in vitro.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Oral administration of GSK1482160 significantly reduced accumulation of MC1\n                      <jats:sup>+<\/jats:sup>\n                      and Alz50\n                      <jats:sup>+<\/jats:sup>\n                      misfolded tau in hippocampal regions, which was accompanied with reduced accumulation of Tsg101, an exosome marker, in hippocampal neurons. Proximity ligation assay demonstrated complex formation of Alz50\n                      <jats:sup>+<\/jats:sup>\n                      tau and Tsg101 in hippocampal neurons, which was reduced by GSK1482160. On the other hand, GSK1482160 had no effect on microglial ramification or CD68 expression, which was significantly enhanced in P301S mice, or pro\/anti-inflammatory cytokine gene expression. Strikingly, GSK1482160-treated P301S mice show significantly improved working and contextual memory as determined by Y-maze and fear conditioning tests. GSK1482160 also significantly increased accumulation of Tsg101 and CD81 in microglia in vivo\n                      <jats:italic>,<\/jats:italic>\n                      suggesting its suppression of P2RX7-induced exosome secretion from microglia\n                      <jats:italic>.<\/jats:italic>\n                      This effect was confirmed in vitro, as ATP-induced secretion of tau-containing exosome was significantly suppressed by GSK1482160 treatment from primary murine microglia, but not\u00a0from neurons or astrocytes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The oral administration of P2RX7 inhibition mitigates disease phenotypes in P301S mice, likely by suppressing release of microglial exosomes. P2RX7 could be a novel therapeutic target for the early stage tauopathy development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13024-020-00396-2","type":"journal-article","created":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T08:03:21Z","timestamp":1597737801000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":143,"title":["P2RX7 inhibitor suppresses exosome secretion and disease phenotype in P301S tau transgenic mice"],"prefix":"10.1186","volume":"15","author":[{"given":"Zhi","family":"Ruan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Delpech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinidhi","family":"Venkatesan Kalavai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia A.","family":"Van Enoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqiao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiko","family":"Ikezu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3979-8596","authenticated-orcid":false,"given":"Tsuneya","family":"Ikezu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,18]]},"reference":[{"key":"396_CR1","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/nn.4132","volume":"18","author":"H Asai","year":"2015","unstructured":"Asai H, et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci. 2015;18:1584\u201393..","journal-title":"Nat Neurosci"},{"key":"396_CR2","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.3233\/JAD-160371","volume":"54","author":"S Baker","year":"2016","unstructured":"Baker S, Polanco JC, Gotz J. Extracellular vesicles containing P301L mutant tau accelerate pathological tau phosphorylation and oligomer formation but do not seed mature neurofibrillary tangles in ALZ17 mice. J Alzheimers Dis. 2016;54:1207\u201317.","journal-title":"J Alzheimers Dis"},{"key":"396_CR3","doi-asserted-by":"crossref","first-page":"9477","DOI":"10.1038\/s41598-019-45676-0","volume":"9","author":"A Crotti","year":"2019","unstructured":"Crotti A, et al. BIN1 favors the spreading of tau via extracellular vesicles. Sci Rep. 2019;9:9477.","journal-title":"Sci Rep"},{"key":"396_CR4","doi-asserted-by":"crossref","unstructured":"Kaczmarek-Hajek K, et al. Re-evaluation of neuronal P2X7 expression using novel mouse models and a P2X7-specific nanobody. Elife. 2018;7:e36217.","DOI":"10.7554\/eLife.36217"},{"key":"396_CR5","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/nrd2605","volume":"7","author":"G Burnstock","year":"2008","unstructured":"Burnstock G. Purinergic signalling and disorders of the central nervous system. Nat Rev Drug Discov. 2008;7:575\u201390.","journal-title":"Nat Rev Drug Discov"},{"key":"396_CR6","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.arr.2015.10.001","volume":"24","author":"M Tewari","year":"2015","unstructured":"Tewari M, Seth P. Emerging role of P2X7 receptors in CNS health and disease. Ageing Res Rev. 2015;24:328\u201342.","journal-title":"Ageing Res Rev"},{"key":"396_CR7","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1097\/01.jnen.0000240470.97295.d3","volume":"65","author":"JG McLarnon","year":"2006","unstructured":"McLarnon JG, Ryu JK, Walker DG, Choi HB. Upregulated expression of purinergic P2X(7) receptor in Alzheimer disease and amyloid-beta peptide-treated microglia and in peptide-injected rat hippocampus. J Neuropathol Exp Neurol. 2006;65:1090\u20137.","journal-title":"J Neuropathol Exp Neurol"},{"key":"396_CR8","doi-asserted-by":"crossref","first-page":"13309","DOI":"10.1074\/jbc.M209478200","volume":"278","author":"LK Parvathenani","year":"2003","unstructured":"Parvathenani LK, et al. P2X7 mediates superoxide production in primary microglia and is up-regulated in a transgenic mouse model of Alzheimer's disease. J Biol Chem. 2003;278:13309\u201317.","journal-title":"J Biol Chem"},{"key":"396_CR9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.immuni.2017.06.020","volume":"47","author":"F Di Virgilio","year":"2017","unstructured":"Di Virgilio F, Dal Ben D, Sarti AC, Giuliani AL, Falzoni S. The P2X7 receptor in infection and inflammation. Immunity. 2017;47:15\u201331.","journal-title":"Immunity."},{"key":"396_CR10","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.4049\/jimmunol.176.7.3877","volume":"176","author":"D Ferrari","year":"2006","unstructured":"Ferrari D, et al. The P2X7 receptor: a key player in IL-1 processing and release. J Immunol. 2006;176:3877\u201383.","journal-title":"J Immunol"},{"key":"396_CR11","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.4049\/jimmunol.179.3.1913","volume":"179","author":"Y Qu","year":"2007","unstructured":"Qu Y, Franchi L, Nunez G, Dubyak GR. Nonclassical IL-1 beta secretion stimulated by P2X7 receptors is dependent on inflammasome activation and correlated with exosome release in murine macrophages. J Immunol. 2007;179:1913\u201325.","journal-title":"J Immunol"},{"key":"396_CR12","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.4049\/jimmunol.173.2.1202","volume":"173","author":"HL Wilson","year":"2004","unstructured":"Wilson HL, Francis SE, Dower SK, Crossman DC. Secretion of intracellular IL-1 receptor antagonist (type 1) is dependent on P2X7 receptor activation. J Immunol. 2004;173:1202\u20138.","journal-title":"J Immunol"},{"key":"396_CR13","doi-asserted-by":"crossref","first-page":"5080","DOI":"10.1016\/j.bmcl.2010.07.033","volume":"20","author":"MH Abdi","year":"2010","unstructured":"Abdi MH, et al. Discovery and structure-activity relationships of a series of pyroglutamic acid amide antagonists of the P2X(7) receptor. Bioorg Med Chem Lett. 2010;20:5080\u20134.","journal-title":"Bioorg Med Chem Lett"},{"key":"396_CR14","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2125.2012.04320.x","volume":"75","author":"Z Ali","year":"2013","unstructured":"Ali Z, et al. Pharmacokinetic and pharmacodynamic profiling of a P2X7 receptor allosteric modulator GSK1482160 in healthy human subjects. Br J Clin Pharmacol. 2013;75:197\u2013207.","journal-title":"Br J Clin Pharmacol"},{"key":"396_CR15","volume":"6","author":"H Takeuchi","year":"2011","unstructured":"Takeuchi H, et al. P301S mutant human tau transgenic mice manifest early symptoms of human tauopathies with dementia and altered sensorimotor gating. PLoS One. 2011;6:e21050.","journal-title":"PLoS One"},{"key":"396_CR16","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0197-4580(00)00157-3","volume":"21","author":"CL Weaver","year":"2000","unstructured":"Weaver CL, Espinoza M, Kress Y, Davies P. Conformational change as one of the earliest alterations of tau in Alzheimer's disease. Neurobiol Aging. 2000;21:719\u201327.","journal-title":"Neurobiol Aging"},{"key":"396_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2005.11.001","volume":"28","author":"V Haroutunian","year":"2007","unstructured":"Haroutunian V, Davies P, Vianna C, Buxbaum JD, Purohit DP. Tau protein abnormalities associated with the progression of alzheimer disease type dementia. Neurobiol Aging. 2007;28:1\u20137.","journal-title":"Neurobiol Aging"},{"key":"396_CR18","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature23002","volume":"547","author":"AWP Fitzpatrick","year":"2017","unstructured":"Fitzpatrick AWP, et al. Cryo-EM structures of tau filaments from Alzheimer's disease. Nature. 2017;547:185\u201390.","journal-title":"Nature."},{"key":"396_CR19","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/(SICI)1097-4547(19970415)48:2<128::AID-JNR5>3.0.CO;2-E","volume":"48","author":"GA Jicha","year":"1997","unstructured":"Jicha GA, Bowser R, Kazam IG, Davies P. Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J Neurosci Res. 1997;48:128\u201332.","journal-title":"J Neurosci Res"},{"key":"396_CR20","doi-asserted-by":"crossref","first-page":"9340","DOI":"10.1523\/JNEUROSCI.22-21-09340.2002","volume":"22","author":"B Allen","year":"2002","unstructured":"Allen B, et al. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci. 2002;22:9340\u201351.","journal-title":"J Neurosci"},{"key":"396_CR21","doi-asserted-by":"crossref","first-page":"104512","DOI":"10.1016\/j.nbd.2019.104512","volume":"130","author":"Y You","year":"2019","unstructured":"You Y, Ikezu T. Emerging roles of extracellular vesicles in neurodegenerative disorders. Neurobiol Dis. 2019;130:104512.","journal-title":"Neurobiol Dis"},{"key":"396_CR22","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.tins.2019.02.007","volume":"42","author":"JC Delpech","year":"2019","unstructured":"Delpech JC, Herron S, Botros MB, Ikezu T. Neuroimmune crosstalk through extracellular vesicles in health and disease. Trends Neurosci. 2019;42:361\u201372.","journal-title":"Trends Neurosci"},{"key":"396_CR23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/978-1-4939-2742-5_15","volume":"1318","author":"S Bagchi","year":"2015","unstructured":"Bagchi S, Fredriksson R, Wallen-Mackenzie A. In situ proximity ligation assay (PLA). Methods Mol Biol. 2015;1318:149\u201359.","journal-title":"Methods Mol Biol"},{"key":"396_CR24","first-page":"5553","volume":"126","author":"M Colombo","year":"2013","unstructured":"Colombo M, et al. Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the heterogeneity of extracellular vesicles. J Cell Sci. 2013;126:5553\u201365.","journal-title":"J Cell Sci"},{"key":"396_CR25","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.neuron.2006.09.023","volume":"52","author":"PA Arguello","year":"2006","unstructured":"Arguello PA, Gogos JA. Modeling madness in mice: one piece at a time. Neuron. 2006;52:179\u201396.","journal-title":"Neuron."},{"key":"396_CR26","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41380-018-0108-3","volume":"24","author":"E Martin","year":"2019","unstructured":"Martin E, et al. New role of P2X7 receptor in an Alzheimer's disease mouse model. Mol Psychiatry. 2019;24:108\u201325.","journal-title":"Mol Psychiatry"},{"key":"396_CR27","doi-asserted-by":"crossref","first-page":"11929","DOI":"10.1523\/JNEUROSCI.1860-14.2014","volume":"34","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34:11929\u201347.","journal-title":"J Neurosci"},{"key":"396_CR28","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.neuron.2007.01.010","volume":"53","author":"Y Yoshiyama","year":"2007","unstructured":"Yoshiyama Y, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337\u201351.","journal-title":"Neuron."},{"key":"396_CR29","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0166-4328(99)00186-2","volume":"110","author":"MS Fanselow","year":"2000","unstructured":"Fanselow MS. Contextual fear, gestalt memories, and the hippocampus. Behav Brain Res. 2000;110:73\u201381.","journal-title":"Behav Brain Res"},{"key":"396_CR30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/978-1-4939-8994-2_10","volume":"1916","author":"AK Kraeuter","year":"2019","unstructured":"Kraeuter AK, Guest PC, Sarnyai Z. The Y-maze for assessment of spatial working and reference memory in mice. Methods Mol Biol. 2019;1916:105\u201311.","journal-title":"Methods Mol Biol"},{"key":"396_CR31","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.neurobiolaging.2003.11.005","volume":"25","author":"AM Hejl","year":"2004","unstructured":"Hejl AM, Glenthoj B, Mackeprang T, Hemmingsen R, Waldemar G. Prepulse inhibition in patients with Alzheimer's disease. Neurobiol Aging. 2004;25:1045\u201350.","journal-title":"Neurobiol Aging"},{"key":"396_CR32","doi-asserted-by":"crossref","first-page":"5704","DOI":"10.1016\/j.febslet.2005.09.047","volume":"579","author":"T Taniguchi","year":"2005","unstructured":"Taniguchi T, et al. Transgenic mice expressing mutant (N279K) human tau show mutation dependent cognitive deficits without neurofibrillary tangle formation. FEBS Lett. 2005;579:5704\u201312.","journal-title":"FEBS Lett"},{"key":"396_CR33","doi-asserted-by":"crossref","first-page":"13896","DOI":"10.1073\/pnas.202205599","volume":"99","author":"Y Tatebayashi","year":"2002","unstructured":"Tatebayashi Y, et al. Tau filament formation and associative memory deficit in aged mice expressing mutant (R406W) human tau. Proc Natl Acad Sci U S A. 2002;99:13896\u2013901.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"396_CR34","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/31508","volume":"393","author":"M Hutton","year":"1998","unstructured":"Hutton M, et al. Association of missense and 5 '-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702\u20135.","journal-title":"Nature."},{"key":"396_CR35","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejphar.2017.12.006","volume":"820","author":"H Jin","year":"2018","unstructured":"Jin H, et al. Synthesis and in vitro characterization of a P2X7 radioligand [(123) I]TZ6019 and its response to neuroinflammation in a mouse model of Alzheimer disease. Eur J Pharmacol. 2018;820:8\u201317.","journal-title":"Eur J Pharmacol"},{"key":"396_CR36","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s11481-017-9768-z","volume":"13","author":"AM DeLeo","year":"2018","unstructured":"DeLeo AM, Ikezu T. Extracellular vesicle biology in Alzheimer's disease and related Tauopathy. J NeuroImmune Pharmacol. 2018;13:292\u2013308.","journal-title":"J NeuroImmune Pharmacol"},{"key":"396_CR37","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11302-016-9546-z","volume":"13","author":"MW Metzger","year":"2017","unstructured":"Metzger MW, et al. Genetically dissecting P2rx7 expression within the central nervous system using conditional humanized mice. Purinerg Signal. 2017;13:153\u201370.","journal-title":"Purinerg Signal"},{"key":"396_CR38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100760","volume":"9","author":"S Dujardin","year":"2014","unstructured":"Dujardin S, et al. Ectosomes: a new mechanism for non-exosomal secretion of tau protein. PLoS One. 2014;9:e100760.","journal-title":"PLoS One"},{"key":"396_CR39","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/ana.23627","volume":"72","author":"C Verderio","year":"2012","unstructured":"Verderio C, et al. Myeloid microvesicles are a marker and therapeutic target for neuroinflammation. Ann Neurol. 2012;72:610\u201324.","journal-title":"Ann Neurol"},{"key":"396_CR40","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11302-009-9132-8","volume":"5","author":"Y Qu","year":"2009","unstructured":"Qu Y, Dubyak GR. P2X7 receptors regulate multiple types of membrane trafficking responses and non-classical secretion pathways. Purinergic Signal. 2009;5:163\u201373.","journal-title":"Purinergic Signal"},{"key":"396_CR41","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239\u201359.","journal-title":"Acta Neuropathol"},{"key":"396_CR42","doi-asserted-by":"crossref","unstructured":"Puangmalai N, et al. Internalization mechanisms of brain-derived tau oligomers from patients with Alzheimer's disease, progressive supranuclear palsy and dementia with Lewy bodies. Cell Death Dis. 2020;11(5):314.","DOI":"10.1038\/s41419-020-2503-3"},{"key":"396_CR43","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41586-020-2156-5","volume":"580","author":"JN Rauch","year":"2020","unstructured":"Rauch JN, et al. LRP1 is a master regulator of tau uptake and spread. Nature. 2020;580:381.","journal-title":"Nature"},{"key":"396_CR44","doi-asserted-by":"crossref","unstructured":"You Y, et al. Activated human astrocyte-derived extracellular vesicles modulate neuronal uptake, differentiation and firing. J Extracellular Vesicles. 2020;9:1706801.","DOI":"10.1080\/20013078.2019.1706801"},{"key":"396_CR45","doi-asserted-by":"crossref","unstructured":"McAvoy KM, et al. Cell-autonomous and non-cell autonomous effects of neuronal BIN1 loss in vivo. PLoS One. 2019;14:e0220125.","DOI":"10.1371\/journal.pone.0220125"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-020-00396-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-020-00396-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-020-00396-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T19:50:58Z","timestamp":1629229858000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-020-00396-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,18]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["396"],"URL":"https:\/\/doi.org\/10.1186\/s13024-020-00396-2","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,18]]},"assertion":[{"value":"5 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"We declare no conflict of interest in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}